New daily pill could shield kids from TB
NCT ID NCT07124559
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a 28-day daily combination of two drugs, rifapentine and isoniazid, to prevent tuberculosis (TB) in children under 13. About 144 children, some with HIV and some without, will join to find the right dose and check for side effects. The goal is to see if this short daily treatment is safe and works for kids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rifapentine and isoniazid (daily for 28 days)
What this could lead to
If successful, this could provide a safe and effective daily TB prevention regimen for children, including those with HIV.
What could go wrong
This is an early phase trial with only 144 children, so the dose and safety are still being determined. Side effects or lack of effectiveness may limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor-Uganda (Site ID: 31798)
Kampala, Uganda
-
Chiangrai Prachanukroh Hospital (Site ID: 5116)
Chiang Rai, 57000, Thailand
-
Gaborone (Site ID: 12701)
Gaborone, Botswana
-
Harare Family Care (Site ID: 31890)
Belgravia, Harare, Zimbabwe
-
Kenya Medical Research Institute, Walter Reed Project Clinical Research Center (Site ID: 5121)
Kericho, 20200, Kenya
-
Les Centres GHESKIO (Site ID: 30022)
Port-au-Prince, HT-6110, Haiti
-
MU-JHU Care Limited (Site ID: 5126)
Kampala, Uganda
-
Molepolole (Site ID: 12702)
Gaborone, Botswana
-
Seke North (Site ID: 30306)
Belgravia, Harare, Zimbabwe
-
Siriraj Hospital, Mahidol University (Site ID: 5115)
Bangkok, Bangkoknoi, 10700, Thailand
-
St Mary's (Site ID: 30303)
Chitungwiza, Zimbabwe